GOVERNMENT COUNSEL, LLC for APOTEX CORPORATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Federal policy relating to market access barriers for generic pharmaceuticals, strengthening domestic generic production and addressing drug shortages.
Foreign entity interest: Artemis Parent, Inc., Artemis Intermediate Holdings Inc., and Apotex Holdco Inc., the parent companies of Apotex Corp., and Apotex Inc., its affiliate, identified by the registrants first quarter 2024 LD-2 report, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner. |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| APOTEX HOLDCO INC. (ONTARIO REGISTERED)(HOLDCO) | Canada | Canada | 100.0% | — |
| APOTEX INC. | Canada | Canada | 100.0% | — |
| ARTEMIS INTERMEDIATE HOLDINGS, INC. (ONTARIO REGISTERED)(AIHI) | Canada | Canada | 100.0% | — |
| ARTEMIS PARENT, INC. | Canada | Canada | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.